The withdrawal of rofecoxib

被引：17
作者：
Arellano, FM [1 ]
机构：
[1] Risk Management Resources, Madison, NJ 07830 USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2005年 / 14卷 / 03期
关键词：
D O I：
10.1002/pds.1077
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
[No abstract available]
引用
收藏
页码：213 / 217
页数：5
相关论文
共 52 条
[1]  
[Anonymous], NATL HLTH EXAMINATIO
[2]  
[Anonymous], Congestive Heart Failure (CHF)
[3]  
Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71
[4]   Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease - A reappraisal [J].
Baigent, C ;
Patrono, C .
ARTHRITIS AND RHEUMATISM, 2003, 48 (01) :12-20
[5]   Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. [J].
Bombardier, C ;
Laine, L ;
Reicin, A ;
Shapiro, D ;
Burgos-Vargas, R ;
Davis, B ;
Day, R ;
Ferraz, MB ;
Hawkey, CJ ;
Hochberg, MC ;
Kvien, TK ;
Schnitzer, TJ ;
Weaver, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (21) :1520-1528
[6]  
BURTON TM, 2003, WALL STREET J 1030
[7]  
Catella-Lawson F, 1999, J PHARMACOL EXP THER, V289, P735
[8]   Selective COX-2 inhibitors, NSAIDs, aspirin, myocardial infarction [J].
Dalen, JE .
ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (10) :1091-1092
[9]  
DAVIS LJ, MORE EVIDENCE VIOXX
[10]  
Day R, 2003, J RHEUMATOL, V30, P642
123456